The Estronex Profile with Bone Resorption measures six important estrogen metabolites, as well as current bone loss. Assessment includes:
The "Good" Estrogen
- 2-hydroxyestrone (2-OHE1) - high levels of 2-OHE1 are ideal to reduce cancer growth.
- 2-hydroxyestradiol (2-OHE2) - shown to exhibit anti-carcinogenic effects.
- 2-methoxyestrone (2-OMeE1) - OMeE1 has shown to have anticancer effects and is ideal in high levels.
- 4-methoxyestrone (4-OMeE1) - as a non-cancerous metabolite, OMeE1 generally does not require treatment at high levels in the body.
The "Bad" Estrogen
- 4-hydroxyestrone (4-OHE1) - considered a "bad" estrogen, 4-OHE1 levels should be low, as high levels may react negatively with damaged DNA.
- 16-α-hydroxyestrone (16α-OHE1) - also considered a "bad" estrogen, 16α-OHE1 in high levels may encourage tumor development.
- 2-OHE:16α-OHE1 (2:16 ratio) - 2:16 ratios less than 2.0 indicate increasing long-term risk for breast, cervical, and other estrogen sensitive cancers. Importantly, nutritional interventions can help raise Estronex 2:16 ratios and decrease long-term risk. Studies also indicate that this risk is modifiable!
- 2-OHE1:2-OMeE1 - a high level of 2-OHE1:2-OMeE1 may also indicate imbalanced estrogen metabolism and low activity in the COMT gene. Evaluation of methylation activity is recommended.
Collagen Breakdown (follow same treatment as "The Ratios", et al)
Deoxypyridinoline - a fragment of Type I collagen breakdown that contains the cross-linking point and has been demonstrated to be more specific to bone resorption than breakdown fragments measured in some earlier assays.
0145 - Estronex Profile with Bone Resorption
- UPLC Tandem Mass Spectrometry